by emma
21. September 2011 13:07
Pfizer is to invest $200 million at its Grange Castle biotechnology manufacturing site in Clondalkin, County Dublin.
The new investment will see Pfizer introduce two new processing suites to expand its current production and product testing capabilities.
Frank D’Amelio, Chief Financial Officer, Pfizer, says “Ireland is a prime location for this major investment” after a “long history in pharmaceutical excellence”.
The biotechnology manufacturing facility is already one of the largest in the world and produces two of Pfizer’s main products, Prevnar and Enbrel.
More than 1,100 staff are currently employed at the site. Irish Prime Minister Enda Kenny says that the new investment highlights “the tremendous contribution to Ireland’s life sciences industry since it (Pfizer) first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment”.
In total, Pfizer has 4,300 staff employed across the country in eight separate locations in Cork, Dublin, Kildare and Limerick. Its latest investment means the company’s outlay now exceeds $7 billion in the country.
1ed5d619-afb3-420b-9248-d9b37eb093cb|0|.0
Tags: Pfizer, investment, invest, 200 million, Grange Castle, biotechnology, biotech, manufacturing, Clondalkin, County Dublin, Ireland, Frank D'Amelio, CFO, Chief Financial Officer, pharma, pharmaceutical, pf, pharmafield, pharma field, pharmaceuticalfield, pharmaceutical field, industry, sector, business, company, facility, Prevnar, Enbrel, Enda Kenny, staff, employee, employer, employed, employment, medical sales, medical sale, Cork, Kildare, Limerick
News
Subscribe